Orbactiv
Total Payments
$1.2M
Transactions
9,959
Doctors
4,514
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $159,684 | 85 | 36 |
| 2023 | $266,091 | 73 | 38 |
| 2022 | $62,998 | 169 | 120 |
| 2021 | $92,321 | 1,855 | 1,082 |
| 2020 | $97,081 | 1,891 | 1,048 |
| 2019 | $247,019 | 4,270 | 2,314 |
| 2018 | $255,280 | 1,616 | 1,031 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $498,874 | 139 | 42.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $302,781 | 159 | 25.6% |
| Food and Beverage | $229,229 | 9,436 | 19.4% |
| Consulting Fee | $79,575 | 30 | 6.7% |
| Travel and Lodging | $41,136 | 178 | 3.5% |
| Grant | $24,500 | 2 | 2.1% |
| Education | $4,380 | 15 | 0.4% |
Payments by Type
General
$681,601
9,820 transactions
Research
$498,874
139 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infection | Melinta Therapeutics, LLC | $341,173 | 1 |
| An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS) | Melinta Therapeutics, LLC | $92,946 | 1 |
| An Open-label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin Single-Dose Infusion in Pediatric Subjects less than 18 Years of Age with Suspected or Confirmed Bacterial Infections | Melinta Therapeutics, LLC | $49,470 | 1 |
| An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (meropenem-vaborbactam) in Pediatric Subjects from Birth to Less Than 18 Years of Age with Serious Bacterial Infections | Melinta Therapeutics, LLC | $13,736 | 0 |
| Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting | Melinta Therapeutics, LLC | $1,550 | 0 |
Top Doctors Receiving Payments for Orbactiv — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , DPM | Foot & Ankle Surgery | Burbank, CA | $218.57 | 5 |
| , DO | Emergency Medicine | Tampa, FL | $218.29 | 2 |
| , DPM | Foot & Ankle Surgery | Woodbridge, VA | $218.04 | 11 |
| , DPM | Primary Podiatric Medicine | Des Plaines, IL | $217.39 | 14 |
| , D.O | Internal Medicine | Elgin, IL | $214.43 | 12 |
| , M.D | Emergency Medicine | Houston, TX | $214.40 | 12 |
| , M.D | Infectious Disease | Tampa, FL | $213.90 | 12 |
| , MD | Infectious Disease | Huntsville, AL | $213.07 | 10 |
| , M.D | Internal Medicine | Houston, TX | $212.96 | 11 |
| , D.O | Internal Medicine | Fort Worth, TX | $212.72 | 2 |
| , MD | Internal Medicine | Ft Worth, TX | $212.72 | 2 |
| , DPM | Podiatrist | Ashtabula, OH | $211.71 | 10 |
| , M.D | Infectious Disease | Coral Springs, FL | $210.68 | 12 |
| , MD | Internal Medicine | Macon, GA | $210.67 | 14 |
| , DPM | Podiatrist | Scotia, NY | $209.92 | 2 |
| , D.O | Emergency Medicine | Oklahoma Citty, OK | $209.66 | 3 |
| , DPM | Podiatrist | Ashtabula, OH | $208.94 | 10 |
| , MD | Family Medicine | Laredo, TX | $207.66 | 2 |
| , DPM | Foot & Ankle Surgery | Darby, PA | $206.67 | 7 |
| , DO | Surgery | Dothan, AL | $204.90 | 11 |
| , D.P.M | Podiatrist | Campbellsville, KY | $203.08 | 12 |
| , MD | Infectious Disease | Manhattan, KS | $199.24 | 11 |
| , DPM | Foot & Ankle Surgery | Glendale, CA | $198.40 | 5 |
| , M.D | Infectious Disease | San Antonio, TX | $198.36 | 14 |
| , DO | Emergency Medicine | Oklahoma City, OK | $197.81 | 2 |
Ad
Manufacturing Companies
- Melinta Therapeutics, LLC $678,176
- Melinta Therapeutics, Inc. $502,299
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 4,514
- Transactions 9,959
About Orbactiv
Orbactiv is a drug associated with $1.2M in payments to 4,514 healthcare providers, recorded across 9,959 transactions in the CMS Open Payments database. The primary manufacturer is Melinta Therapeutics, Inc..
Payment data is available from 2018 to 2024. In 2024, $159,684 was paid across 85 transactions to 36 doctors.
The most common payment nature for Orbactiv is "Unspecified" ($498,874, 42.3% of total).
Orbactiv is associated with 5 research studies, including "A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infection" ($341,173).